Stay updated with breaking news from Daniel Vitt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
Immunic Inc (NASDAQ:IMUX) said the results from the part C portion of its phase 1 clinical trial of IMU-856 in patients with celiac disease are positive,...
Issuer: Immunic, Inc. / Key word(s): Study results Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders 04.05.2023 / 12:30 CET/CEST The issuer is solely responsib...
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
Issuer: Immunic, Inc. / Key word(s): Study results Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic